NCT06534814 Development and Application of an Artificial Intelligence-driven Accurate Identification Model for Gastric Cancer Lymph Node Metastasis
| NCT ID | NCT06534814 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hebei Medical University |
| Condition | The Primary Focus of This Study is on Gastric Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-07-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2024-07-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The clinical trial titled "Development and Application of an Artificial Intelligence-Driven Accurate Identification Model for Gastric Cancer Lymph Node Metastasis" aims to enhance the detection and treatment of gastric cancer through the utilization of cutting-edge artificial intelligence (AI) technology. This study will develop an AI-driven model designed to accurately identify lymph node metastasis in patients with gastric cancer, which is crucial for staging the disease and planning effective treatment strategies. The trial will involve a multidisciplinary team of oncologists, radiologists, data scientists, and AI experts who will collaborate to create a robust and precise identification system. Participants will undergo standard diagnostic procedures, and the AI model will analyze imaging and pathological data to predict lymph node involvement. By comparing the AI model's predictions with traditional diagnostic methods, the study seeks to validate the model's accuracy and efficiency. This approach is expected to improve early detection rates, reduce diagnostic errors, and ultimately lead to better clinical outcomes for patients with gastric cancer. The successful implementation of this AI-driven model could revolutionize the current standards of care and serve as a blueprint for integrating AI technologies in other cancer diagnoses and treatments.
Eligibility Criteria
Inclusion Criteria: 1. Diagnosis of Gastric Cancer: Confirmed diagnosis of gastric cancer, either newly diagnosed or recurrent. 2. Lymph Node Involvement: Suspected or confirmed involvement of lymph nodes, as indicated by imaging studies or pathology reports. 3. Age: Patients aged 18 years or older. 4. Performance Status: An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, indicating a functional status that allows participation in the study. 5. Informed Consent: Ability to provide written informed consent to participate in the study. Exclusion Criteria: 1. Pregnancy or Lactation: Pregnant or lactating women, due to potential risks to the fetus or infant. 2. Severe Comorbid Conditions: Presence of severe comorbid medical conditions that could interfere with the study or pose additional risks. 3. Previous AI-Driven Diagnostic Intervention: Prior use of any AI-driven diagnostic models specifically for gastric cancer lymph node metastasis. 4. Inability to Comply: Inability or unwillingness to comply with study procedures, including follow-up visits and data collection. 5. Mental or Cognitive Impairment: Conditions that impair the ability to provide informed consent or participate effectively in the study.
Frequently Asked Questions
Who can join the NCT06534814 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying The Primary Focus of This Study is on Gastric Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06534814 currently recruiting?
Yes, NCT06534814 is actively recruiting participants. Visit ClinicalTrials.gov or contact Hebei Medical University to inquire about joining.
Where is the NCT06534814 trial being conducted?
This trial is being conducted at Shijiazhuang, China.
Who is sponsoring the NCT06534814 clinical trial?
NCT06534814 is sponsored by Hebei Medical University. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.